# Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

> **NCT07233668** · NA · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 172 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma ( mRCC)

## Interventions

- **DRUG:** Ipilimumab plus Nivolumab
- **PROCEDURE:** Cytoreductive Nephrectomy

## Key facts

- **NCT ID:** NCT07233668
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233668, "Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07233668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*